Phase I study of a B-HDM regimen for elderly multiple myeloma patients

Phase I study of a B-HDM regimen for elderly multiple myeloma patients - B-HDM regimen

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009668

Enrollment

Registered

2013-01-01

Start date

2013-01-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma

Interventions

B-HDM

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: According to the International Myeloma Working Group (IMWG) criteria20, patients younger than 70 years with symptomatic MM were eligible for this trial.

Exclusion criteria

Exclusion criteria: The exclusion criteria were a serum creatinine level<2.05 mg/dL at time of high-dose therapy (HDT), liver dysfunction (e.g., a serum total bilirubin level<2.0 mg/dL, or serum aspartate/alanine aminotransferase or alkaline phosphatase levels more than 2.5 times the upper limit of normal), grade 3 or worse peripheral neuropathy, significant comorbidity that would preclude ASCT, poor performance status (&#61619;grade 3), and a history of any other malignancy with the exception of basal cell carcinoma and stage I cervical cancer.

Design outcomes

Primary

Measure	Time frame
safty	—

Secondary

Measure	Time frame
efficacy	—

Countries

Japan

Contacts

Public ContactNaoki Takezako

National Hospital Organization Disaster Medical Center of Japan Department of Hematology

ntakezak@tdmc.hosp.go.jp042-526-5511

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026